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Lymphoplasmacytic lymphoma (LPL) is a low-grade B-cell
non-Hodgkin lymphoma that typically involves the bone
marrow, lymph nodes and spleen and usually has an
indolent course. Transformation to a diffuse large B-cell
lymphoma (DLBCL) is rare [1], but when it occurs, prog-
nosis is poor [2].
The myeloid differentiation primary response gene 88
(MYD88) p.(L265P)) is a somatic mutation that activates
the NFjB pathway and is found in different types of
B-cell non-Hodgkin lymphoma. This mutation most fre-
quently occurs in LPL, in which detection of the mutation
is of diagnostic as well as therapeutic value [3–5].
Ibrutinib is Bruton’s tyrosine kinase (BTK) inhibitor that
inactivates the NFjB pathway [6]. It is registered for the
use in mantle cell lymphoma, chronic lymphocytic leukemia
and Waldenstr€om macroglobulinemia (LPL with presence of
M-protein in the serum). However, there are no data on
the use of BTK inhibitor therapy in patients with trans-
formed LPL. Here we present a patient with transformed
LPL and loss of MYD88 p.(L265P), showing a significant clin-
ical response to ibrutinib treatment for both systemic as
well as central nervous system (CNS) localizations.
A 63 year old female patient presented in 2014 with
B-symptoms and pancytopenia due to extensive bone
marrow infiltration with LPL (Figure 1). The lymphoma
predominantly consisted of small lymphocytes without
prominent nucleoli. Occasionally, there was plasmacytic
differentiation present. The lymphocytes showed immu-
nohistochemical expression of B-cell markers (e.g. CD20
and CD79A), as well as scattered positivity for plasma cell
markers (e.g. CD138). In addition, the plasmacytic B-cells
displayed monotypia for kappa.
At that time, there was no extramedullary localization
or M-protein in the serum. The patient was treated with
eight cycles ofrituximab, cyclophosphamide, doxorubicin,
vincristine, prednisolone (R-CHOP) chemotherapy and
achieved complete remission. Hereupon, she was treated
with rituximab maintenance therapy.
In 2015, the patient developed vertigo, ataxia and dip-
lopia and a subsequent MRI demonstrated two brain
tumors (Figure 2). CT scan of the neck, chest and abdo-
men and bone marrow biopsy showed no evidence of
systemic lymphoma recurrence. A lumbar puncture was
performed and a kappa positive clonal lymphocytic prolif-
eration was detected by flow cytometric immunopheno-
typing of the cerebrospinal fluid (CSF). The patient was
diagnosed with CNS relapse of the LPL. No biopsy of the
brain lesions was performed as they were poorly access-
ible. Treatment with high dose systemic methotrexate
(MTX), alternating with rituximab, dexamethason, high
dose cytarabine and cisplatinum (R-DHAP) and intrathecal
MTX was started. After three cycles, stem cell mobilization
was planned, but this was unsuccessful despite plerixafor
administration. Three additional high dose MTX courses
were given. Subsequent CSF samples and MRI demon-
strated complete remission.
In April 2016 a new lesion developed in a subman-
dibular lymph node and B-symptoms recurred. A biopsy
of the submandibular lymph node was performed, which
was consistent with DLBCL (Figure 1), non-germinal cen-
ter type according to the Hans’ immunohistochemical
algorithm and without translocation of BCL-2, BCL-6
and cMYC. Diagnostic work-up, consisting of a CT scan
(Figure 2), bone marrow biopsy and brain MRI demon-
strated no other signs of systemic recurrent lymphoma.
However, the CSF showed again kappa positive clonal
lymphocytes by immunophenotyping, demonstrating CNS
relapse.
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The patient was diagnosed with transformed LPL and
concurrent localization in the CSF. In addition, clonality
analysis was performed according to the Identiclone assay
(Invivoscribe) [7], showed that the B-cell clone detected in
the lymph node, the diagnostic bone marrow aspirate
(2014) and the first CSF sample (2015) were identical.
Remarkably, MYD88 p.(L265P) was detected by droplet
digital PCR (ddPCR) in the bone marrow biopsy (2014;
mutation frequency 23.3% with an assay sensitivity of
2.1%) and CSF sample (2015; mutation frequency 42.0%
with an assay sensitivity of 3.9%), but not in the lymph
node biopsy (2016; assay sensitivity 1.2%) (Figure 1).
As the patient was considered to be refractory to
chemotherapy, treatment with a daily dose of 420mg
ibrutinib was started. Levels of ibrutinib were measured
in the blood and CSF, using liquid chromatography-tan-
dem mass spectrometry [8]. Serum ibrutinib levels,
16 hours after administration, were 20.1 ± 0.9 ng/mL and
were also positive in the CSF (<5 (0.43 ± 0.24) ng/mL;
approximately 2% of the serum level), which is in accord-
ance with previous publications [9].
Within two days after start of ibrutinib therapy an
extremely fast response occurred, with complete clinical
resolution of the enlarged submandibular lymph node,
which was confirmed by CT scan after 16 weeks of ther-
apy. In addition, B-symptoms disappeared as well,
although some CNS related symptoms persisted. CSF
examination was repeated after three months of therapy
which demonstrated a persistence of clonal B lympho-
cytes, albeit with a decline in number. Also, clonality
Figure 1. Loss of MYD88 p.(L265P) during transformation of LPL (2014) to DLBCL (2016). Morphology (HE) of bone marrow (a)
and lymph node biopsy (b) showing small lymphocytes without prominent nucleoli and blastoid lymphocytes with prominent
nucleoli respectively. Ki67 staining of bone marrow (c) and lymph node biopsy (d) showing low and high proliferation index
respectively. ddPCR for MYD88 p.(L265P) mutation of bone marrow (e) and lymph node biopsy (f) showing presence and absence
of MYD88 p.(L265P) respectively. Upper left quadrant (blue): mutant positive droplets. Lower right quadrant (green): wild-type
positive droplets. Lower left quadrant (grey): negative droplets, depicting droplets without measurable PCR product. Abbreviations:
DLBCL: diffuse large B-cell lymphoma; ddPCR: droplet digital polymerase chain reaction; HE: hematoxylin & eosin staining; LPL:
lymphoplasmacytic lymphoma.


























analysis on this CSF sample detected the same clone as
before. Interestingly, no MYD88 p.(L265P) was detected in
this CSF sample by ddPCR (assay sensitivity 1.5%), which
is concordant with loss of this mutation in the DLBCL of
the submandibular lymph node biopsy (2016).
The patient remained in stable clinical remission for
five months. She then presented with an epileptic seizure
due to a new brain lesion. The patient received whole
brain radiotherapy but with minimal clinical effect. She
died one month later after a total period of six months of
ibrutinib treatment.
To our knowledge, this is the first report of a patient
with transformed LPL, who has shown a remarkably fast
and prolonged response to ibrutinib monotherapy, 420mg
once daily. The patient retained a clinical remission for five
months after start of treatment, although she eventually
died as a result of progressive CNS lymphoma. Even
though the presence of ibrutinib was demonstrated in the
CSF, measured levels (<5 ng/mL) were probably too low
for proper clearance of all pathological B-cells.
Although the same B-cell clone was detected in the
bone marrow aspirate (2014), CSF samples (2015 and
2016) and lymph node biopsy (2016), MYD88 p.(L265P)
was present in the bone marrow aspirate (2014) and first
CSF sample (2015), but could not be detected in the
lymph node biopsy (2016) and last CSF sample (2016).
Loss of MYD88 p.(L265P) might be explained by clonal
selection as a result of BTK inhibitor therapy, leading to
expansion of a MYD88 p.(L265P) negative subclone.
However, loss of MYD88 p.(L265P) already occurred before
start of ibrutinib treatment. Furthermore, as MYD88
p.(L265P) regards a driver mutation [10,11], it seems
unlikely that loss of this mutation would occur as a result
of clonal evolution. Despite the loss of the MYD88
p.(L265P), our patient still responded to BTK inhibitor ther-
apy. It could be hypothesized that an alternative BTK-acti-
vating mechanism was involved, such as CD79B mutation,
which results in chronic active B-cell receptor signaling
[12,13]. Interestingly, CD79B mutation has been reported in
75% of transformed LPL patients [14]. On the other hand,
response to ibrutinib treatment has also been described in
DLBCLs ABC-type, classified according to gene expression
profiling, without MYD88 mutations or other targets of
ibrutinib, such as CD79B [13]. This indicates that an activat-
ing mutation is not a prerequisite for effective BTK inhibitor
treatment. Unfortunately, there was not enough material
left for further genetic analysis.
In conclusion, the described case shows clinically rele-
vant activity of ibrutinib in transformed LPL, despite loss
of MYD88 p.(L265P) during transformation. This under-
lines the need to further investigate mechanisms for loss
of MYD88 p.(L265P) during LPL transformation, as well as
the need to further investigate the use of BTK inhibitor
therapy in transformed LPL.
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